Company Profile

Tango Therapeutics Stock Price, News & Analysis

United StatesBiotechnologyNASDAQ

Company overview

Business overview

Tango Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, Tango Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.

Business Model Characteristics

Tango Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.

Position Within the Biotechnology Landscape

Compared with more mature healthcare names, Tango Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.

Why the stock is moving

TNGX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

Future catalysts

Tango’s catalysts are its synthetic-lethality oncology programs and any update that shows the platform can still produce meaningful clinical differentiation. The company is still heavily data-dependent.

Recent news

The five most recent feed items are shown below in reverse chronological order.

  1. 01
  2. 02
  3. 03

    Tango Therapeutics Appoints Sung Lee to Board of Directors

    Source: Tango Therapeutics

  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.